Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1835-1844

  Hao, Mu ^a   Zang, Meirong ^a   Wendlandt, Erik ^b   Xu, Yan ^a   An, Gang ^a   Gong, Dasen ^c   Li, Fei ^a   Qi, Fang ^a   Zhang, Yanru ^a   Yang, Ye ^b   Zhan, Fenghuang ^b   Qiu, Lugui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b UNIVERSITY OF IOWA   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; MiR 19a; Multiple myeloma; Prognostic indicator; Serum miRNAs

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MICRORNA; MICRORNA 135B 5P; MICRORNA 19A; MICRORNA 214 3P; MICRORNA 33B; MICRORNA 3658; MICRORNA 4254; MICRORNA 92A; THALIDOMIDE; UNCLASSIFIED DRUG; MIRN19 MICRORNA, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; BLOOD; CHEMISTRY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SERUM;

ADULT; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SERUM; TRANSCRIPTOME;

EID: 84922567750     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29199     Document Type: Article

References (58)

1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324-39.
2. Anderson KC, Shaughnessy JD, Jr, Barlogie B, et al. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002:214-40.
3. Vicente-Duenas C, Romero-Camarero I, Garcia-Criado FJ, et al. The cellular architecture of multiple myeloma. Cell Cycle 2012;11:3715-17.
4. Yang Y, Shi J, Tolomelli G, et al. RARalpha2 expression confers myeloma stem cell features. Blood 2013;122:1437-47.
5. Zhou W, Yang Y, Xia J, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013;23:48-62.
6. Zhou W, Yang Y, Gu Z, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia 2014;28:1155-8.
7. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107:1987-96.
8. Yyusnita Y, Norsiah MD, Zakiah I, et al. Micro-RNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray. Malays J Pathol 2012;34:133-43.
9. Sevcikova S, Kubiczkova L, Sedlarikova L, et al. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2013;54:189-91.
10. Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:511-18.
11. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature 2008;455:64-71.
12. Grosshans H, Filipowicz W. Molecular biology: the expanding world of small RNAs. Nature 2008;451:414-16.
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
14. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
15. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
16. Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012;120:3958-67.
17. Wu P, Agnelli L, Walker BA, et al. Improved risk stratification in myeloma using a microRNAbased classifier. Br J Haematol 2013;162:348-59.
18. Dimopoulos K, Gimsing P, Gronbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013;91:95-105.
19. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-e26.
20. Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010;107:7904-9.
21. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18.
22. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
23. An G, Xu Y, Shi L, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica 2014;99:353-9.
24. Zhu W, Yang L, Shan H, et al. MicroRNA expression analysis: clinical advantage of propranolol reveals key microRNAs in myocardial infarction. PLoS One 2011;6:e14736.
25. Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011;124:175-84.
26. Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012;188:5500-10.
27. Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010;6:e1000879.
28. Yan HL, Xue G, Mei Q, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009;28:2719-32.
29. Lin ZY, Huang YQ, Zhang YQ, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer 2014;135:541-50.
30. Eguchi T, Watanabe K, Hara ES, et al. OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One 2013;8:e58796.
31. Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9.
32. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
33. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
34. Gilad S, Meiri E, Yogev Y, et al. Serum micro-RNAs are promising novel biomarkers. PLoS One 2008;3:e3148.
35. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21.
36. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
37. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008;111:3183-9.
38. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012;32:326-48.
39. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
40. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
41. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
42. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
43. Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2012;2:e53.
44. Halimi M, Parsian H, Asghari SM, et al. Clinical translation of human microRNA 21 as a potential biomarker for exposure to ionizing radiation. Transl Res 2014;163:578-84.
45. Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013;49:3442-9.
46. Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011;52:1787-94.
47. Hao M, Zhang L, An G, et al. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 2011;4:37.
48. Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014;28:1922-6.
49. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
50. Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011;5:281-91.
51. Ouchida M, Kanzaki H, Ito S, et al. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One 2012;7:e44095.
52. Lin TL, Wang QH, Brown P, et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One 2010;5:e15262.
53. Yu L, Simonson OE, Mohamed AJ, et al. NF-kappaB regulates the transcription of protein tyrosine kinase Tec. FEBS J 2009;276:6714-24.
54. Ye H, Liu X, Lv M, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 2012;40:5201-14.
55. Li ZW, Chen H, Campbell RA, et al. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008;15:391-9.
56. Grillari J, Hackl M, Grillari-Voglauer R. miR-17-92 cluster: ups and downs in cancer and aging. Biogerontology 2010;11:501-6.
57. Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009;23:2839-49.
58. Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013;434:688-94.